We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current PJP market cap is 284.95M. The company's latest EPS is USD 0.0222 and P/E is 3753.15.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 5.44M | 4.7M | 5.79M | 4.61M | 4.27M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | -3.2M | 80.79M | -3.72M | 8.3M | 76k |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 365.31M | 362.83M | 381.75M | 343.75M | 310.08M |
| Total Liabilities | 8.81M | 4.32M | 61.27M | 38.15M | 46.05M |
| Total Equity | 356.5M | 358.5M | 320.48M | 305.6M | 264.04M |
| Market Cap | 284.95M |
| Price to Earnings Ratio | 3753.15 |
| Price to Sales Ratio | 66.7 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 1.08 |
| Dividend Yield | - |
| Shares Outstanding | 3.42M |
| Average Volume (1 week) | 9.64k |
| Average Volume (1 Month) | 10.06k |
| 52 Week Change | 8.24% |
| 52 Week High | 89.87 |
| 52 Week Low | 75.326 |
| Spread (Intraday) | 9.52 (10.78%) |
| Company Name | Invesco Pharmaceuticals ETF |
| Address |
155 federal st boston, massachusetts 02110 |
| Website | https://www.invescopowershares.com |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
